Skip to content
Open access

Circadian rhythm amplification in diabetic retinopathy: a pilot study

Aug 2026 · SLEEP Advances · Vol 7 · 0 citations · 36 references
Medicine

Abstract

Abstract Study Objectives Data suggested that diabetic retinopathy (DR) may be associated with a dysregulated melatonin rhythm and disturbed sleep. This pilot study explored the effects of a novel behavioral intervention “Amplify-RHYTHM” in type 2 diabetes (T2D) with DR. Materials and Methods Eight T2D persons (5M/3F, mean age 57.2 years) with DR participated in a 6-week “Amplify-RHYTHM” intervention, consisting of sleep stability (remote weekly coaching and educational content), and timed light exposure (morning bright light exposure, evening blue light reduction, and nightly light-blocking sleep mask). Data were collected before and after the intervention. Primary outcomes were insomnia symptoms and 14-day actigraphy-derived sleep parameters. Circadian-related parameters included rest–activity rhythm parameters, dim light melatonin onset (n = 5), and overnight urinary 6-sulfatoxymelatonin. Cardiometabolic parameters included glucose levels from a 14-day continuous glucose monitor, high sensitivity C-reactive protein, resting blood pressure, and heart rate. Statistical analysis was performed using paired t-tests or Wilcoxon signed rank tests. Results Compared to baseline, after Amplify-RHYTHM intervention, insomnia symptoms significantly decreased (p = .041), variability of sleep midpoint reduced (0.90 [0.27] vs. 1.33 [0.39] h, p = .018), and intradaily variability decreased (0.82 [0.13] vs. 0.95 [0.21], p = .049). Urinary 6-sulfatoxymelatonin remained low and the dim light melatonin onset was unchanged. High sensitivity C-reactive protein significantly decreased, 1.58 (2.29) versus 2.36 (3.3) mg/L, p = .011, but heart rate change was nonsignificant (p = .065). Continuous glucose monitor glucose levels and blood pressure did not change. Conclusion Amplify-RHYTHM resulted in less insomnia symptoms, more regular sleep, reduced behavioral circadian fragmentation, and reduced systemic inflammation. These pilot data should be confirmed in a larger, randomized study. Clinical Trials The study was registered at www.clinicaltrials.gov, NCT06183476.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.